Keeping Track: US FDA Approvals Include Novel Agents Zepzelca And Uplizna, Biosimilar Nyvepria, Follow-On Semglee

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Keeping Track Feature image

Biologics products took center stage last week, on both the approval and submission sides – until Jazz Pharmaceuticals PLC and PharmaMar SA’s novel alkylating drug Zepzelca nabbed US FDA approval two months before its user fee goal date.

Pfizer Inc.’s Nyvebria and Mylan NV and Biocon Ltd.’s Semglee took different regulatory paths to approval. Nyvebria,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers